At Johns Hopkins, Alex “Sarge” Sargent is a lecturer for the MS in Biotechnology program.
Sargent also is the director of Process Development of Cell and Gene Therapy at Charles River Laboratories. He has worked at several large companies on drug discovery and the research and development of groundbreaking cell and gene therapies. These include Lonza, where he patented new technologies for cell therapy manufacturing and CRISPR gene editing, and AstraZeneca, where he worked to bring new chimeric antigen receptor T-cell therapies into clinical trials.
He obtained his PhD from Case Western Reserve University in Cleveland, Ohio, where he studied the challenges and promises of stem cell biology, neuroimmunology, and Cleveland sports teams. He then went on to the Lerner Research Institute at the Cleveland Clinic Foundation to continue his research in stem cell biology and neural regeneration.
Sargent is passionate about the challenge of curing cancer, working on cell and gene therapy process and analytical development from discovery through regulatory submission, manufacturing, and clinical trials. He wakes up each day excited to help advance cell and gene therapy to treat and cure disease, with the steadfast goal of improving human lives.